Lederfoline

Folinic acid, the active ingredient in Lederfoline, is a folate analog (antimetabolite) presented as an oral formulation for prescription use. It is employed to reduce toxicity of fluoropyrimidine chemotherapy, to rescue patients after high‑dose methotrexate, and to treat folate deficiency in appropriate clinical settings.

GNH USA supplies Lederfoline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lederfoline is a folate analog used in oncology and metabolic support pathways. It addresses several clinically recognised conditions: - Adjunct to fluoropyrimidine chemotherapy: reduces toxicity and supports efficacy of 5‑FU or capecitabine regimens. - Rescue after high‑dose methotrexate: restores reduced folate pools to prevent severe myelosuppression. - Treatment of folate deficiency: replenishes folate stores in patients with inadequate dietary intake or malabsorption.

Lederfoline may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may require hydration. - Rash: skin erythema or mild itching. - Headache: transient cranial discomfort. - Fatigue: generalised tiredness. - Mild elevation of liver enzymes.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal dysfunction: acute kidney injury in susceptible individuals. - Hepatic toxicity: marked transaminase rise or hepatitis. - Bone marrow suppression: pancytopenia or severe neutropenia. - Thromboembolic events: rare clot formation.

Before prescribing Lederfoline, clinicians should consider several safety measures. - Renal function: assess baseline creatinine clearance and monitor during therapy. - Hepatic function: evaluate liver enzymes and adjust use if significant impairment exists. - Concurrent methotrexate: avoid overlapping high‑dose schedules to prevent additive toxicity. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lederfoline can interact with several medicines; awareness of the interaction level guides management.

Major Interactions (Avoid): - High‑dose methotrexate: concurrent use may exacerbate toxicity. - Antifolate agents (e.g., pemetrexed): antagonistic effect reduces efficacy of both drugs. - Leucovorin rescue timing: improper timing can diminish intended protective effect.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin): monitor renal parameters closely. - Hepatotoxic agents (e.g., azathioprine): observe liver function tests regularly. - Vitamin B12 deficiency: may alter folate metabolism and response to therapy.